About our Research Department
Our clinical research experience dates back to 2005. We have been involved in a multitude of clinical trials and, due to our success as a clinical site, have strong relationships with many leading pharmaceutical companies. Our Research Division is headed by Asha Bailey, D.O., Medical Director of Research. The Assistant Medical Directors are Howard Lifland, M.D. and Brian Powell, M.D. with Catherine Mack as our Clinical Research Manager. All providers at Columbia Nephrology are actively engaged in research and our team is dedicated to the purpose of research and fulfilling our role as clinical investigators. Our team holds the utmost regard to the ethical nature of the studies along with providing the best care to our patients.
Our dedicated Research Department has extensive experience in conducting Phase II–IV clinical trials. As a site, we continue to play a prominent role in high-profile industry-sponsored observational studies and interventional clinical trials. With a combined total of over 37 years of research experience focused on nephrology, our research staff has the ability to ethically and knowledgeably conduct clinical trials with patient safety being our main focus. Our expansive facility has a local laboratory, a lab processing area for trials utilizing central labs, a dedicated research area and ample amount of exam rooms to facilitate study visits.
Our studies have included the following indications:
- Chronic Kidney Disease
- Diabetic Nephropathy
- Anemia Management
- Polycystic Kidney Disease
- Bone Mineral Metabolism
- Vascular Access
- Akebia Therapeutics, Inc.
- FibroGen, Inc.
- Vascular Therapies, Inc.
- AbbVie, Inc.
- Otsuka Pharmaceuticals, Inc.
- Amgen, Inc.
- Hospira, Inc.
- Frenova Renal Research
Current Enrolling Trials:
Our site has ongoing clinical trials in CKD and dialysis and we are currently looking for patients to participate in the following clinical trials:
- Anemia in patients with chronic kidney disease
- Anemia in patients with end stage renal disease
- Patients diagnosed with Focal Segmental Glomerulosclerosis (FSGS), Immunoglobulin A Nephropathy (IgAN), Minimal Change Disease (MCD) or Membranous Nephropathy (MN)
- Patients on dialysis needing a dialysis access placement
If you would like to get more information on any of the ongoing clinical trials offered at Columbia Nephrology, please fill out the Trial Interest form and our Research Department will be in contact with you to discuss your participation.